# Luxna Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/luxna-biotech-co

- Industry: Biotechnology
- Headquarters: Suita-shi, Japan
- Website: www.luxnabiotech.co.jp
- Total disclosed funding: $20M
- Latest round: Series C (Aug 7, 2025)
- Investors on record: 14

## About

Founded in 2017 and based in Osaka, Japan, Luxna Biotech Co., Ltd. engages in the nucleic acid editing business. The firm also engages in drug creation, such as oligonucleotide therapeutics, and cancer research. The company develops nucleic acid drugs using artificial nucleic acids with pharmaceutical and chemical companies. Nucleic acid medicines utilize DNA and RNA molecules to treat diseases. These therapies have the potential to revolutionize treatment options for conditions such as genetic disorders and cancers by harnessing the body’s biological mechanisms. In? August 2025,? Luxna Biotech Co.,Ltd. raised? JPY 150 million?in?series C funding? from new investors new investors Mitsubishi UFJ Capital, Kobe University Capital and Resona Capital. The company plans to use its proceeds from August 2025 funding to enhance its business development, collaborating on drug discovery with pharmaceutical firms, promoting technology out-licensing partnerships, and expedite its drug discovery pipeline.

## Funding rounds

- Series C, Aug 7, 2025, $1M — Mitsubishi UFJ Capital, Resona Capital, Kobe University Capital
- Series C, Sep 6, 2024, $1.7M — Daiwa Corporate Investment, Osaka University Venture Capital, TOHOKU University Venture Partners
- Series B, Dec 16, 2021, $11M — Nippon Venture Capital, Mizuho Capital, Osaka University Venture Capital, Shinsei Capital Partners, Healthcare Innovation, UBE
- Series A, Feb 10, 2020, $5.9M — Mizuho Capital, Senshu Ikeda Capital, Osaka University Venture Capital, Summit Pharmacy, Nissan Chemical Industries, Ltd.
- Series A, Mar 1, 2018, $0.9M — Osaka University Venture Capital

## Investors

- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A, Series B, Series C
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A, Series B
- Senshu Ikeda Capital (https://capitalatlas.ai/funds/senshu-ikeda-capital) — Series A
- Summit Pharmacy — Series A
- Nissan Chemical Industries, Ltd. — Series A
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series B
- Shinsei Capital Partners (https://capitalatlas.ai/funds/shinsei-capital-partners) — Series B
- Healthcare Innovation — Series B
- UBE — Series B
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- TOHOKU University Venture Partners (https://capitalatlas.ai/funds/tohoku-university-venture-partners) — Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Resona Capital (https://capitalatlas.ai/funds/resona-capital) — Series C
- Kobe University Capital (https://capitalatlas.ai/funds/kobe-university-capital) — Series C